

Food and Drug Administration  
Center for Food Safety and Applied Nutrition  
Office of Special Nutritionals

ARMS#

12740




0 - FRONT

76425  
12740

CESAN Page \_\_\_\_ of \_\_\_\_

## A. Patient information

1 Patient identifier  In confidence	2 Age at time of event: <u>31</u> or _____ Date of birth: _____	3 Sex <input checked="" type="checkbox"/> female <input type="checkbox"/> male	4 Weight ____ lbs or ____ kgs
---	---	--	--

## B. Adverse event or product problem

1 <input checked="" type="checkbox"/> Adverse event and/or <input type="checkbox"/> Product problem (e.g. defects, malfunctions)	
2 Outcomes attributed to adverse event (check all that apply) <input type="checkbox"/> death (mo/day/yr) <input type="checkbox"/> life-threatening <input checked="" type="checkbox"/> hospitalization (initial or prolonged) <input type="checkbox"/> disability <input type="checkbox"/> congenital anomaly <input type="checkbox"/> required intervention to prevent permanent impairment/damage <input type="checkbox"/> other _____	
3 Date of event (mo/day/yr) <u>5/10/97</u>	4 Date of this report (mo/day/yr) <u>1/22/98</u>

5 Describe event or problem  
 Pt. admitted on 5/10/97 to CC of Providence in the West & nervousness. Was taking "Ripped Fuel", a wt-loss substance obtained from \_\_\_\_\_. Had been taking x1 week; initially 1 TID, then 1 TID. Ripped Fuel contains: Mahuang Extract 334mg (6% ephedra extract) & guarana extract (910mg, 22% caffeine) / capsule. Pt. found to have bruxism & short run of VT, which persisted through 5/12 on 1st hr.

6 Relevant tests/laboratory data, including dates  
Final test:  
 Stage 1 - HR 64, BP 139/85, O2sat 94,  
 Stage 2 - HR 90, BP 131/86, O2sat 99  
 Stage 3 - HR 120, BP 114/56, O2sat 100  
 Stage 4 - HR 84, BP 74/34, O2sat 97  
Loss of urinary antidiuretic product

7 Other relevant history, including preexisting medical conditions (e.g., allergies, race, pregnancy, smoking and alcohol use, hepatic/renal dysfunction, etc.)

Non-contributory

## C. Suspect medication(s)

1 Name (give labeled strength & mfr. labeler, if known) #1 <u>Ripped Fuel: Mahuang Extract 334mg</u> <u>Guarana Extract 910mg</u>	
2 Dose, frequency & route used #1 <u>1 TID x 1 wk, 1 to</u> #2 <u>1 TID x 1 day PTA</u>	3 Therapy dates (if unknown, give duration) from/to (or best estimate) #1 <u>1 wk prior to admission</u> #2 _____
4 Diagnosis for use (indication) #1 <u>wt. loss</u> #2 _____	5. Event abated after use stopped or dose reduced #1 <input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> doesn't apply #2 <input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> doesn't apply
6 Lot # (if known) #1 _____ #2 _____	7 Exp. date (if known) #1 _____ #2 _____
8. Event reappeared after reintroduction #1 <input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> doesn't apply #2 <input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> doesn't apply	
9 NDC # (for product problems only) #1 _____ #2 _____	


10. Concomitant medical products and therapy dates (exclude treatment of event)  
Pt. on atenolol 50mg OD.

## D. Suspect medical device

1 Brand name		4. Operator of device <input type="checkbox"/> health professional <input type="checkbox"/> lay user/patient <input type="checkbox"/> other _____	
2 Type of device		5 Expiration date (mo/day/yr)	
3 Manufacturer name & address		7 If implanted, give date (mo/day/yr)	
6 model #		8 If explanted, give date (mo/day/yr)	
catalog #			
serial # <u>JAN 28 1993</u>			
lot # <u>MEDWATCH OTU</u>			
other #			
9 Device available for evaluation? (Do not send to FDA) <input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> returned to manufacturer on _____ (mo/day/yr)			

10 Concomitant medical products and therapy dates (exclude treatment of event)  
000001

## E. Reporter (see confidentiality section on back)

1 Name, address & phone # 			
2 Health professional? <input checked="" type="checkbox"/> yes <input type="checkbox"/> no	3 Occupation <u>Pharm. D.</u>	4 Also reported to <input type="checkbox"/> manufacturer <input type="checkbox"/> user facility <input type="checkbox"/> distributor	
5 If you do NOT want your identity disclosed to the manufacturer, place an X in this box <input type="checkbox"/>			



Mail to: MEDWATCH  
5600 Fishers Lane  
Rockville, MD 20852-9787  
or FAX to: 1-800-FDA-0178

# ADVICE ABOUT VOLUNTARY REPORTING

## Report experiences with:

- medications (drugs or biologics)
- medical devices (including in-vitro diagnostics)
- special nutritional products (dietary supplements, medical foods, infant formulas)
- other products regulated by FDA

## Report **SERIOUS** adverse events. An event is serious when the patient outcome is:

- death
- life-threatening (real risk of dying)
- hospitalization (initial or prolonged)
- disability (significant, persistent or permanent)
- congenital anomaly
- required intervention to prevent permanent impairment or damage

## Report even if:

- you're not certain the product caused the event
- you don't have all the details

## Report product problems – quality, performance or safety concerns such as:

- suspected contamination
- questionable stability
- defective components
- poor packaging or labeling

## How to report:

- just fill in the sections that apply to your report
- use section C for all products except medical devices
- attach additional blank pages if needed
- use a separate form for each patient
- report either to FDA or the manufacturer (or both)

## Important numbers:

- 1-800-FDA-0178 to FAX report
- 1-800-FDA-7737 to report by modem
- 1-800-FDA-1088 for more information or to report quality problems
- 1-800-822-7967 for a VAERS form for vaccines

**If your report involves a serious adverse event with a device** and it occurred in a facility outside a doctor's office, that facility may be legally required to report to FDA and/or the manufacturer. Please notify the person in that facility who would handle such reporting.

**Confidentiality:** The patient's identity is held in strict confidence by FDA and protected to the fullest extent of the law. The reporter's identity may be shared with the manufacturer unless requested otherwise. However, FDA will not disclose the reporter's identity in response to a request from the public, pursuant to the Freedom of Information Act.

The public reporting burden for this collection of information has been estimated to average 30 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send your comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to:

Reports Clearance Officer, PHS  
Hubert H. Humphrey Building,  
Room 721-B  
200 Independence Avenue, S.W.  
Washington, DC 20201  
ATTN: PRA

and to:  
Office of Management and  
Budget  
Paperwork Reduction Project  
(0910-0230)  
Washington, DC 20503

Please do NOT  
return this form  
to either of these  
addresses.

FDA Form 3500-back

Please Use Address Provided Below – Just Fold In Thirds, Tape and Mail

## Department of Health and Human Services

Public Health Service  
Food and Drug Administration  
Rockville, MD 20857

## Official Business

Penalty for Private Use \$300

## BUSINESS REPLY MAIL

FIRST CLASS MAIL PERMIT NO. 946 ROCKVILLE, MD

POSTAGE WILL BE PAID BY FOOD AND DRUG ADMINISTRATION

**MEDWATCH**

The FDA Medical Products Reporting Program  
Food and Drug Administration  
5600 Fishers Lane  
Rockville, MD 20852-9787



NO POSTAGE  
NECESSARY  
IF MAILED  
IN THE  
UNITED STATES  
OR APO/FPO



000002

RECEIVED  
CLINICAL RESEARCH  
& REVIEW/OSN HFS-452

